Pancreatic Cancer Research

ResearcherSir Run Run Shaw HospitalActive in the last 2 years

Weiwei Jin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2974-9598; OpenAlex author ID A5102904270. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
36
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 2 papers · 2023: 5 papers · 2024: none · 2025: none · 2026: 2 papers

Papers 14

  1. 18F-FDG PET Radiomic Analysis to Predict Occult Liver Metastases of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.acra.2025.10.024↗
  2. CLEC4G Promotes Pancreatic Cancer Progression by Suppressing Cathepsin B-Mediated Ferroptosis: Evidence From Mendelian Randomization Study and Experimental Val… Last author DOI 10.1155/humu/7359548↗
  3. Correction: Functions and clinical applications of exosomes in Pancreatic cancer. Last author DOI 10.1007/s11033-023-08906-3↗
  4. Biological characteristics of pancreatic ductal adenocarcinoma: Initiation to malignancy, intracellular to extracellular. Last author DOI 10.1016/j.canlet.2023.216391↗
  5. Causal effect between gut microbiota and pancreatic cancer: a two-sample Mendelian randomization study. Last author DOI 10.1186/s12885-023-11493-y↗
  6. Factors predicting recurrence after left‑sided pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-023-03080-z↗
  7. Protocadherin-1 serves as a prognostic biomarker and promotes pancreatic cancer progression by suppressing CD8+ T cell infiltration through CCL5-CCR5 axis. Last author PMID 38058826↗
  8. Functions and clinical applications of exosomes in pancreatic cancer. Last author DOI 10.1007/s11033-022-07765-8↗
  9. Clinical outcome comparison of laparoscopic radical antegrade modular pancreatosplenectomy vs. laparoscopic distal pancreatosplenectomy for left-sided pancreat… Co-author DOI 10.3389/fsurg.2022.981591↗
  10. Laparoscopic pancreaticoduodenectomy versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: oncologic outcomes and long-term survival. Co-author DOI 10.1007/s00464-019-06968-8↗
  11. Role of Treg/Th17 Imbalance, Microbiota and miRNAs in Pancreatic Cancer: Therapeutic Options. Co-author DOI 10.1615/critrevimmunol.2020033631↗
  12. Laparoscopic pancreaticoduodenectomy for pancreatic cancer: a hope or hype? Co-author DOI 10.21037/hbsn-20-356↗
  13. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis. First author DOI 10.1186/s40880-019-0410-8↗
  14. LDP vs ODP for pancreatic adenocarcinoma: a case matched study from a single-institution. Co-author DOI 10.1186/s12876-015-0411-2↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yiping Mou · 13 shared papers, 2015–2026 · strength 2.18
  2. Zhichen Jiang · 6 shared papers, 2022–2026 · strength 1.38
  3. Hui‐Ju Wang · 4 shared papers, 2022–2023 · strength 0.80
  4. Yuanyu Wang · 3 shared papers, 2020–2026 · strength 0.56
  5. Yucheng Zhou · 4 shared papers, 2019–2023 · strength 0.52
  6. Li Li · 2 shared papers, 2023 · strength 0.39
  7. Mingyang Liu · 2 shared papers, 2023 · strength 0.36
  8. Peng Xu · 2 shared papers, 2022–2023 · strength 0.32
  9. J J Chen · 1 shared paper, 2026 · strength 0.30
  10. Nan Niu · 2 shared papers, 2020–2022 · strength 0.26
  11. Chao Lu · 2 shared papers, 2019–2020 · strength 0.20
  12. Ou Li · 1 shared paper, 2023 · strength 0.19
  13. Mingyang Liu · 1 shared paper, 2023 · strength 0.19
  14. Shaobo Zhang · 1 shared paper, 2023 · strength 0.17
  15. Xiaohao Zheng · 1 shared paper, 2023 · strength 0.17
  16. Yunyun Xu · 1 shared paper, 2023 · strength 0.17
  17. Fangxia Wang · 1 shared paper, 2023 · strength 0.17
  18. Tao Xia · 1 shared paper, 2023 · strength 0.17
  19. Tao Xia · 1 shared paper, 2022 · strength 0.15
  20. Yunyun Xu · 1 shared paper, 2022 · strength 0.15
  21. Maohua Cai · 1 shared paper, 2020 · strength 0.13
  22. Ying‐Yu Ma · 1 shared paper, 2020 · strength 0.13
  23. Xue Yang · 1 shared paper, 2020 · strength 0.13
  24. Luo‐Qin Fu · 1 shared paper, 2020 · strength 0.13
  25. Ke Chen · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.